Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide

Completed · Phase 1

Conditions studied: Newly Diagnosed High-Grade Glioma

In brief

The purpose of this study is to find the highest dose of mebendazole (MBZ) that can be safely given to people with malignant brain tumors in combination with the current standard of care (temozolomide) without causing severe side effects. We also want to find out if MBZ can slow the growth of the brain tumor. The study doctors have found that MBZ is effective against malignant brain tumors in the laboratory and animal models of brain tumors.

Key facts

Study ID

NCT01729260

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

24

Starts

2013-04-04

Expected to finish

2021-04-16

Last updated by the study team

2021-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have histologically confirmed newly diagnosed high-grade glioma(WHO Grade III or IV)
• Age ≥18 years
• Karnofsky Performance Score (KPS) ≥ 60%
• Life expectancy greater than 12 weeks
• Patients must have adequate organ and marrow function
• Completed >80% of the prescribed radiation therapy and concurrent temozolomide according to the Stupp regimen without grade 3 or 4 hematologic toxicity
• Patients may have received Gliadel during surgery
• Ability to swallow pills and keep medication record
• women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation.
• Ability to understand and willingness to sign a written informed consent document
• Be able to comply with treatment plan, study procedures and follow-up examinations

You may not qualify if…

• Patients must not have received prior therapy other than standard chemoradiation according to Stupp et al and Gliadel.
• Patients may not be receiving any other investigational agents while on study
• Patients who have known allergy to mebendazole or benzimidazole
• Patients who have previously had a severe side effect, such as agranulocytosis and neutropenia, in conjunction with previous mebendazole or benzimidazole class drug for a parasitic infection
• Patients who are taking metronidazole and cannot be safely moved to a different antibiotic greater than 7 days prior to starting mebendazole therapy
• Patients who have taken any benzimidazole (ABZ, flubendazole, thiabendazole, fenbendazole, triclabendazole, etc.) within the last 3 months
• Patients who are taking any anti-convulsant medication that interferes with the cytochrome P450 pathway (e.g. phenytoin, phenobarbital, carbamazepine, etc.)
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, chronic hepatitis, acute hepatitis, or psychiatric illness/social situation that would limit compliance with study requirements
• Pregnant women are excluded
• Patients with human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive; or with a history of chronic active hepatitis or cirrhosis
• Patients with a history of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the study participation or investigational product administration or may interfere with the interpretation of the results
• Patients who are not available for follow-up assessments or unable to comply with study requirements

Where it is running

• The Johs Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.